16.43

0.18% -0.03

After Hours: 16.42 -0.010 -0.06%

Amylyx Pharmaceuticals Inc (AMLX)

Overview News Price History Option Chain Financials Discussions Forecast

Amylyx Pharmaceuticals Inc stock is traded at $16.43, with a volume of 1.02M. It is down -0.18% in the last 24 hours and up +9.90% over the past month. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Previous Close:

$16.46

Open:

$16.61

24h Volume:

1.02M

Relative Volume:

1.00

Market Cap:

$1.83B

Revenue:

$-665.00K

Net Income/Loss:

$-144.74M

P/E Ratio:

-10.58

EPS:

-1.5527

Net Cash Flow:

$-123.48M

1W Performance:

+0.74%

1M Performance:

+9.90%

6M Performance:

+24.09%

1Y Performance:

+219.03%

1-Day Range:

$15.98

$16.94

1-Week Range:

$15.39

$16.94

52-Week Range:

$4.20

$18.61

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Name

Amylyx Pharmaceuticals Inc

Sector

Healthcare (1106)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

617-682-0917

Address

55 CAMBRIDGE PARKWAY, CAMBRIDGE

Employee

136

Twitter

Next Earnings Date

2026-05-07

Latest SEC Filings

AMLX's Discussions on Twitter

Compare AMLX vs TAK, ZTS, TEVA, HLN, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMLX Amylyx Pharmaceuticals Inc	16.43	1.83B	-665.00K	-144.74M	-123.48M	-1.5527
TAK Takeda Pharmaceutical Co Adr	16.55	52.32B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	112.54	47.38B	9.47B	2.67B	2.28B	6.0218
TEVA Teva Pharmaceutical Industries Ltd Adr	35.86	41.16B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.17	41.02B	14.54B	2.22B	2.58B	0.4871
UTHR United Therapeutics Corp	572.20	24.67B	3.18B	1.33B	1.04B	27.90

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-03-26	Initiated	Stifel	Buy
Jul-10-25	Resumed	Goldman	Buy
Jun-24-25	Initiated	Guggenheim	Buy
Jun-17-25	Initiated	Citigroup	Buy
May-30-25	Initiated	TD Cowen	Buy
Apr-07-25	Upgrade	Mizuho	Neutral → Outperform
Nov-18-24	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-23-24	Upgrade	BofA Securities	Neutral → Buy
Mar-18-24	Downgrade	Mizuho	Buy → Neutral
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Jan-03-24	Initiated	Robert W. Baird	Outperform
Dec-12-23	Initiated	Deutsche Bank	Buy
Jul-24-23	Upgrade	Goldman	Neutral → Buy
Mar-31-23	Initiated	Mizuho	Buy
Jan-05-23	Initiated	BofA Securities	Buy
May-25-22	Initiated	Citigroup	Buy
Apr-01-22	Downgrade	Goldman	Buy → Neutral

View All

Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News

06:00 AM

Amylyx Investors To Get $6.5M In ALS Drug Settlement - Law360

06:00 AM

07:00 AM

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia - Business Wire

07:00 AM

12:04 PM

Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in - BioSpace

12:04 PM

May 03, 2026

MSN Money - MSN

May 03, 2026

H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence - Investing.com

May 03, 2026

May 01, 2026

AMLX Stock Price, Quote & Chart | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill

May 01, 2026

Apr 30, 2026

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 - BioSpace

Apr 30, 2026

Amylyx’s ORION Trial in Progressive Supranuclear Palsy Reaches Completion: What Investors Should Watch - TipRanks

Apr 30, 2026

Press Release: Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 - Moomoo

Apr 30, 2026

Amylyx sets May 7 earnings report, 8 a.m. ET webcast - Stock Titan

Apr 30, 2026

Amylyx Pharmaceuticals (AMLX) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Apr 30, 2026

Bank of America Securities Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX) - The Globe and Mail

Apr 30, 2026

Apr 29, 2026

Mizuho Adjusts Price Target on Amylyx Pharmaceuticals to $21 From $19, Maintains Outperform Rating - marketscreener.com

Apr 29, 2026

Apr 28, 2026

BofA raises Amylyx Pharmaceuticals stock price target on model updates By Investing.com - Investing.com Nigeria

Apr 28, 2026

BofA raises Amylyx Pharmaceuticals stock price target on model updates - Investing.com

Apr 28, 2026

Mizuho raises Amylyx stock price target on lower expense outlook By Investing.com - Investing.com India

Apr 28, 2026

Mizuho Forecasts Strong Price Appreciation for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat

Apr 28, 2026

symbol__ Stock Quote Price and Forecast - CNN

Apr 28, 2026

Mizuho raises Amylyx stock price target on lower expense outlook - Investing.com

Apr 28, 2026

Apr 27, 2026

Amylyx Pharmaceuticals Q3 2025 Earnings Preview - MSN

Apr 27, 2026

Apr 24, 2026